Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

Conditions

• Wet Age-related Macular Degeneration

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) — DRUG
  Patients will be followed-up for 24 months

Study Details

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Key Dates

Start date

Jul 29, 2013

Status verified

Mar 2018

Primary completion

Mar 31, 2017

Completion

Mar 31, 2017

Study Design

Enrollment

988 participants (actual)

Arms

• Arm: Group 1

Primary Outcome Measure

Mean change of visual acuity for the total patient population [ Time Frame: Baseline, 12 and 24 months ]

Related Studies

• MMP-9 Inhibition for Recalcitrant Wet AMD
  PHASE2 · Recruiting · University of Iowa · Iowa City, Iowa
• Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
  PHASE3 · Recruiting · AbbVie · Phoenix, Arizona